Cardiovascular

FDA releases safety review update report for Benicar

As part of a safety review update on cardiovascular events and Benicar (olmesartan), the U.S. Food and Drug Administration states Benicar’s benefits “continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=benicar&SearchType=BasicSearch. Read more at http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares